Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Solid Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,057 result(s) found for: Malignant Solid Tumor. Displaying page 20 of 53.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    EudraCT Number: 2013-004398-28 Sponsor Protocol Number: AA01 Start Date*: 2016-06-17
    Sponsor Name:Medical Research Council Clinical Trials Unit at UCL [...]
    1. Medical Research Council Clinical Trials Unit at UCL
    2. Tata Memorial Centre for India
    Full Title: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
    Medical condition: Cancer (breast, colorectal, gastro-oesophageal and prostate)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003773-42 Sponsor Protocol Number: PM1183-B-005-14 Start Date*: 2015-03-30
    Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal
    Full Title: A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors.
    Medical condition: Selected Advanced Solid Tumors.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003788-82 Sponsor Protocol Number: SA2115 Start Date*: 2022-02-15
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: An open label phase 2 study on propranolol and pembrolizumab in advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma – a Scandinavian Sarcoma Group collaboration
    Medical condition: Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002476 Angiosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025552 Malignant fibrous histiocytoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003079-41 Sponsor Protocol Number: BOLD-100-001 Start Date*: 2023-01-06
    Sponsor Name:Bold Therapeutics, Inc. (Bold)
    Full Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours
    Medical condition: Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017770 Gastric carcinoma LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005199-27 Sponsor Protocol Number: E7080-G000-211 Start Date*: Information not available in EudraCT
    Sponsor Name:Eisai Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily W...
    Medical condition: 131I-refractory differentiated thyroid cancer (DTC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005022-71 Sponsor Protocol Number: C-II-004 Start Date*: 2008-01-17
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research – EWIV
    Full Title: Prospective randomized Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer
    Medical condition: metastatic or locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001456-36 Sponsor Protocol Number: EGF100151 Start Date*: 2004-09-06
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer.
    Medical condition: Solid tumor treatment
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006279 Breast neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004606-60 Sponsor Protocol Number: BP42772 Start Date*: 2021-06-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS W...
    Medical condition: Advanced or metastatic squamous cell carcinoma of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) BE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001695-42 Sponsor Protocol Number: CAN04CLIN004 Start Date*: 2021-07-27
    Sponsor Name:Cantargia AB
    Full Title: A Phase 1/2 study of CAN04, a fully humanised monoclonal antibody against IL1RAP, in combination with different chemotherapy regimens in subjects with advanced solid tumours
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000196-85 Sponsor Protocol Number: IB_2014-01 Start Date*: 2014-09-29
    Sponsor Name:Institut Bergonié
    Full Title: A phase Ib study of metronomic Cyclophosphamide and Methotrexate combined with Zoledronic acid and Sirolimus in patients with solid tumor with bone metastasis and advanced pretreated Osteosarcoma.
    Medical condition: advanced solid tumor with bone metastasis and advanced pretreated osteosarcoma.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000818-36 Sponsor Protocol Number: 2007/04 Start Date*: 2007-06-19
    Sponsor Name:CENTRE ANTOINE LACASSAGNE
    Full Title: Etude de phase III randomisée comparant deux modes d’administration des facteurs de croissance (G-CSF) non pégylés dans la prévention secondaire des neutropénies sévères
    Medical condition: Tumeurs solides malignes bénéficiant d'un traitement par chimiothérapie selon le schéma J1 = J21
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005201-27 Sponsor Protocol Number: D361EC00001 Start Date*: 2022-06-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Cas...
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing) GR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000339-21 Sponsor Protocol Number: JK08.1.01 Start Date*: 2022-08-29
    Sponsor Name:Salubris Biotherapeutics, Inc.
    Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ...
    Medical condition: Unresectable Locally Advanced or Metastatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085663 Clear cell papillary renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077840 Urothelial cancer of renal pelvis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061534 Oesophageal squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10040810 Skin carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014720 Endometrial adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083238 Luminal breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002464-27 Sponsor Protocol Number: IEOS707/412 Start Date*: 2013-06-26
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with solid tumors metastatic or relapsed, resistant/refractory to conventional therapy, using HLA-identical related donors or H...
    Medical condition: solid tumors metastatic or relapsed, resistant/refractory to conventional therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033612 Pancreatic carcinoma NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004213-13 Sponsor Protocol Number: ST101-101 Start Date*: 2020-07-13
    Sponsor Name:Sapience Therapeutics, Inc.
    Full Title: A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
    Medical condition: Castrate-Resistant Prostate Cancer, HR Positive local advanced/metastatic Breast Cancer, Glioblastoma, and Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001111-12 Sponsor Protocol Number: 1367.1 Start Date*: 2015-06-12
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit
    Medical condition: Advanced, unresectable and/or metastatic solid tumours, which have failed with conventional treatment or for which no therapy of proven efficacy exists, or in patients who are not amenable to stand...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012820 Diffuse large B-cell lymphoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010029 Colorectal cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078295 NUT midline carcinoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001471-23 Sponsor Protocol Number: UZBRU_VHH2_1 Start Date*: 2019-02-06
    Sponsor Name:UZ Brussel
    Full Title: Phase I/IIa study to evaluate the safety, biodistribution, radiation dosimetry and tumor imaging potential of 68GaNOTA-Anti-MMR-VHH2, a new radiopharmaceutical for in vivo imaging of Tumour-Associa...
    Medical condition: Tumour associated macrophages found in tumour lesions of two cancer types: breast cancer or melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004684-20 Sponsor Protocol Number: WO29637 Start Date*: 2015-05-27
    Sponsor Name:Roche Farma S.A en nombre de F. Hoffmann-La Roche LTD
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (Anti?PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATEDADVANCED RENAL CELL CARCINOMA
    Medical condition: advanced kidney cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) FR (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005437-53 Sponsor Protocol Number: ITCC053 Start Date*: 2016-11-03
    Sponsor Name:Erasmus Medical Center
    Full Title: A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Study ITCC 053
    Medical condition: Malignancies carrying a genetic alteration of ALK, MET or ROS1
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) IE (Completed) ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002041-22 Sponsor Protocol Number: PKB115131 Start Date*: 2015-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects with Solid Tumors and Hematologic Malignancies
    Medical condition: Multiple myeloma, other heamatologic malignancies, solid tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 08:39:39 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA